Emerging studies suggest this peptide, a dual agonist targeting both incretin and GIP , may represent a notable advancement for obesity loss . Initial patient tests have shown substantial reductions https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide